Trial Profile
A Phase II, Open Label, Single Arm, Multicenter Study of INC280 Administered Orally in Adults With Advanced Hepatocellular Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 04 Jul 2023 Status changed from completed to discontinued.
- 07 Jun 2023 Status changed from active, no longer recruiting to completed.
- 25 May 2023 Planned End Date changed from 5 May 2023 to 24 May 2023.